MedTrace Logo

Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda

NCT01578447 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 356

Last updated 2014-09-18

No results posted yet for this study

Summary

The purpose of this study is to assess acceptability and side effects of a low-dose injectable contraceptive formulation which is delivered under the skin (subcutaneously), as compared with injectable contraception delivered into the muscle (intramuscularly) among adult HIV-positive women who attend mobile clinics for HIV care and wish to use injectable contraception. The investigators will also assess experiences experiences delivering these two types of injections among health care providers working within the HIV care clinics.

Conditions

  • Acceptability of Different Contraceptive Injection Types

Interventions

DRUG

DepoSubQ Provera 104 in Uniject

DepoSubQ Provera 104 in Uniject

DRUG

Intramuscular DMPA

Intramuscular DMPA

Sponsors & Collaborators

  • Society of Family Planning

    collaborator OTHER

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Rakai Health Sciences Program

    collaborator OTHER

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Ron H Gray, MD, MSC · Johns Hopkins Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578447 on ClinicalTrials.gov